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With approximately 1 per 100 babies affected each year, congeni-
tal heart diseases (CHDs) are the most common type of birth 
defect and the number 1 cause of birth-related deaths (1). Though 
numerous CHD phenotypes of various etiologies exist, the major-
ity of patients present with abnormal valves, membranous septa, 
and/or myocardial defects (2). Abnormalities in signaling mole-
cules and/or pathways involved in cardiac development are impli-
cated in CHD pathogenesis; however, the underlying mechanisms 
remain poorly understood and/or unknown.
Primary hypertrophic cardiomyopathy (HCM), which affects the 
cardiac muscle wall, is a common cause of mortality and morbid-
ity in CHD patients (3–5). Although hypertrophy may initially be 
a compensatory response to cardiac stress, over time, HCM can 
decompensate to dilation and end-stage heart failure. Mutations 
in genes that encode sarcomeric proteins, such as the myosin-bind-
ing protein C, β-MHC, and troponin T, and that alter sarcomeric 
structure and function constitute approximately 75% of cases of 
primary HCM (6–9). The remaining approximately 25% are caused 
by mutations in other genes, most of which remain undefined. 
The ultimate effect of all of these mutations is to impose mechani-
cal, biochemical and/or bioenergetic stresses on the heart. These 
stresses activate cardiac signaling pathways, including the RAS/
MAPK pathway, other MAPK (e.g., p38, JUN N terminal kinase 
[JNK]) pathways, the PI3K/AKT pathway, and in some cases the 
RHOA, STAT3, and/or calcineurin/nuclear factor of activated 
T cells pathways, to mediate the hypertrophic phenotype (10).
One non-sarcomeric protein involved in the pathogenesis 
of CHDs is SH2 domain-containing PTP-2 (SHP2), which is 
encoded by the non-receptor protein tyrosine phosphatase (PTP) 
type 11 (PTPN11) gene. SHP2 is a ubiquitously expressed pro-
tein that contains 2 N terminal SH2 domains, a catalytic (PTP) 
domain, and a C terminal tail with 2 tyrosine phosphorylation 
sites and a proline-rich motif (11, 12). SHP2 is regulated by an 
elegant molecular switch mechanism that couples its recruitment 
to appropriate locations in the cell with its catalytic activation 
(13, 14). In the basal state, the backside loop of the N-SH2 of 
SHP2 is wedged into the PTP domain, rendering the PTP domain 
physically and chemically inactive. Binding of a phosphotyrosyl 
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peptide alters the conformation of the N-SH2 domain, preventing 
interaction of the backside loop with the PTP domain, unfolding 
the enzyme, and resulting in phosphatase activation (13–15).
Essential for development and the first PTP known to have a 
functional role in adult myocardium (16, 17), SHP2 plays a key 
role in RAS/MAPK activation in response to most, if not all, recep-
tor tyrosine kinase (RTK), cytokine receptor, GPCR, and integrin 
signaling pathways (18). Moreover, germline PTPN11 mutations 
cause 2 related, but distinguishable, syndromes that include con-
genital heart defects among their features. Essentially all cases of 
LEOPARD syndrome (LS) (MIM151100), a rare autosomal domi-
nant, multisystemic disease, are caused by mutations in PTPN11 
(19). LS is named for its presenting manifestations: multiple len-
tigines, electrocardiographic conduction abnormalities, ocular 
hypertelorism, pulmonic stenosis, abnormal genitalia, retarda-
tion of growth, and sensorineural deafness (20). PTPN11 muta-
tions also cause more than 45% of cases of Noonan syndrome 
(NS) (MIM163950) (21), the more common disorder (~1/2,000 
births), with the remaining cases resulting from mutations in 
SOS1 (22, 23), KRAS (24), NRAS (25), SHOC2 (26), RAF1 (27, 28), 
or as yet unknown genes.
NS and LS are 2 of several autosomal dominant “RASopathies,” 
disorders caused by mutations in various RAS/MAPK pathway 
components (29, 30). Not surprisingly, many of the phenotypic 
abnormalities in NS and LS (and in other RASopathies) are quite 
similar: for example, both are characterized by proportionate 
short stature, facial dysmorphism, and skeletal anomalies (21, 
31). However, their cardiac phenotypes are quite distinct. Pulmo-
nary valve stenosis with dysplastic leaflets and atrial/ventricular 
septal defects are the most prevalent cardiac defects in NS caused 
by PTPN11 mutations (32, 33). By contrast, despite the fact that 
pulmonic stenosis is part of the LS acronym, the most common 
cardiac manifestation of this disorder is HCM (34–38).
We and others previously showed that the biochemical proper-
ties of LS and NS alleles also are quite distinct (39–41), suggesting 
different mechanisms for NS and LS pathogenesis. Whereas NS 
mutants primarily perturb the N-SH2/PTP interface to preferen-
tially “open” the structure to an activated state (39), LS mutations 
typically affect conserved residues important for PTP catalysis 
(e.g., of the 2 most common sites for mutation in LS, Y279 sets the 
depth of the catalytic cleft and T468 lies close to the PTP domain 
“signature motif ”). Almost all NS mutants tested behave as 
gain-of-function mutations of SHP2 and act primarily, if not 
exclusively, to potentiate RAS/MAPK pathway activation (40, 
42–46). By contrast, LS mutants are catalytically impaired and act 
as dominant-negative mutants, impairing ERK activation in tran-
sient and stable transfection assays (39–41).
Together, these findings raise an interesting question: how can 
PTPN11 mutations that result in SHP2 proteins with opposite 
catalytic functions give rise to such similar disease phenotypes? 
Drosophila (47) and Zebrafish (48, 49) models of LS have provid-
ed some insights; however, these data are conflicting. Oishi et 
al. reported that LS mutants enhance Ras/Mapk pathway activ-
ity in Drosophila (47), whereas in Zebrafish studies, Jopling et al. 
and Stewart et al. found that LS mutants have dominant-negative 
effects on this pathway (48, 49). To resolve this paradox and to 
address the above question in a potentially more relevant mam-
malian system, we generated an inducible “knockin” mouse model 
expressing the LS-associated Ptpn11 Y279C mutation (Ptpn11Y279C/+ 
mice). Remarkably, our mice recapitulated nearly all major aspects 
of the LS phenotype. Furthermore, biochemical analyses of hearts 
and primary cardiomyocytes from these mice identify the molecu-
lar basis for HCM in LS and a pharmacological intervention that 
reverses the cardiac defects associated with LS in vivo.
Results
Generation of mice expressing an inducible Ptpn11 Y279C allele. To 
assess the functional consequences of LS mutations, we generated 
knockin mice harboring an inducible, floxed Y279C allele of Ptpn11, 
Ptpn11Y279C/+ mice, hereafter termed iLS/+ mice (Figure 1). We chose 
this allele because PTPN11Y279C is one of the 2 most common LS 
mutations (40, 50). The targeting construct was generated using 
recombination-mediated genetic engineering (recombineering) (51). 
Briefly, a fragment of the mouse Ptpn11 gene containing exons 7–9 
was subcloned from a bacterial artificial chromosome clone into a 
plasmid containing a thymidine kinase (TK) selection cassette (for 
negative selection). The targeting vector itself included a loxP site, 
a Ptpn11 genomic fragment encoding WT exon 7, a loxP511 site, 
an inverted mutant Ptpn11 exon 7 fragment containing the Y279C 
mutation, an inverted loxP site, an inverted loxP511 site, a neo selec-
tion cassette flanked by FRT sites, and the Ptpn11 genomic frag-
ment encoding WT exons 8 and 9 (Figure 1A). The inverted mutant 
Y279C exon 7 also introduced 2 HpyCH4 restriction sites which we 
believe to be novel in the sequence to be used for screening (Figure 
1). This construct, when recombined appropriately into the endog-
enous Ptpn11 locus, directs expression of WT Ptpn11 in the absence 
of Cre recombinase (Cre); these mice are termed iLS/+ mice. Upon 
exposure to Cre, unidirectional recombination (as a consequence of 
the mutant loxP sites) results in expression of the mutant Y279C 
allele; these mice are designated LS/+ mice (Figure 1, A–C).
The targeting construct was electroporated into TC1 (129S6/
SvEv) ES cells and selected with G418 and FIAU. Resistant colonies 
were expanded, and homologous recombinants were identified by 
long-range PCR (Figure 1D and Supplemental Table 1; supple-
mental material available online with this article; doi:10.1172/
JCI44972DS1). Correctly targeted ES cell clones were injected into 
blastocysts and implanted into pseudopregnant mice. Germline 
transmission was achieved, as verified by PCR for the neo gene 
(Figure 1E and Supplemental Table 1). The neo cassette was then 
removed by crossing iLS/+ chimeras to Flp-recombinase–express-
ing mice (Figure 1B), and ubiquitous expression of the LS mutant 
was achieved by mating appropriate progeny from this cross with 
EIIA-Cre (C57BL6/J) mice (Figure 1C). These mice were subsequent-
ly crossed to WT C57BL6/J mice to generate mice with global LS 
expression (LS/+ mice). Two PCR strategies were used to distinguish 
LS/+ mice from WT mice using tail DNA (Figure 1F and Supple-
mental Table 1). Moreover, expression of the mutant allele (at levels 
comparable to that of WT Ptpn11 mRNA) was detected by RT-PCR, 
and the expected products were observed upon HpyCH4 digestion 
(Figure 1G and Supplemental Table 1). LS/+ mice also expressed 
comparable levels of Shp2 protein as compared to those of WT mice 
(data not shown). LS/+ mice were obtained at the expected Mende-
lian ratio at weaning, indicating that on this background, LS expres-
sion was compatible with embryonic development. All experiments 
herein were performed using LS/+ mice (and their WT littermates) 
crossed for at least 4–5 generations on C57BL6/J background.
LS/+ mice demonstrate phenotypic abnormalities similar to those in 
human LS. It was immediately apparent that, compared with WT 
littermates, LS/+ mice had abnormal faces, with distinctly small-
er, more slanted eyes (Figure 2A, top) and a planar nasal bridge 
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(Figure 2A, bottom). Microcomputed tomography (μCT) scans 
showed an increased skull width-to-length ratio in LS/+ mice, 
compared with that in WT controls (Table 1). Together, these 
features gave LS/+ mice the appearance of hypertelorism, even 
though inner canthal distance, while trending wider in LS/+ mice, 
was not statistically different. LS/+ mice also had skeletal/chest 
abnormalities, with pectus carinatum superiorly and pectus exca-
vatum inferiorly (Figure 2B), a common feature of LS patients. 
Although their size was normal at birth (data not shown), by 
weaning, LS/+ mice were significantly smaller than their WT lit-
termates, and they remained so throughout their lives (Figure 2, 
C and D). μCT scans showed that femur length also was decreased 
significantly in LS/+ mice (Table 1). Histological examination 
revealed abnormal genitalia and substantial macrophage accu-
mulation in the organ of Corti (inner ear) in the LS/+ mice, which 
might cause (or indicate) sensorineural defects (data not shown). 
No other phenotypic/organ abnormalities were observed.
Somatic mutations in PTPN11 occur in several types of 
hematologic malignancies, most notably, juvenile myelomono-
cytic leukemia, and, more rarely, in solid tumors. Furthermore, 
approximately 20%–50% of NS patients have some hematologic 
abnormality (52–54). We collected peripheral blood, bone mar-
row, spleen, and thymus from a small cohort of either WT or 
LS/+ mice. Notably, in contrast to mice with NS-associated 
Ptpn11 mutations (43), we observed no apparent abnormalities 
in any hematological parameter in LS/+ mice (data not shown). 
Indeed, LS patients also are not reported to have any highly 
penetrant hematological abnormalities. Taken together, these 
data indicate that the gross morphologic features in LS/+ mice 
closely recapitulate those in LS patients (20, 31, 55).
LS/+ mice have pathological cardiac hypertrophy that transitions to dila-
tion. Over 80% of LS patients develop severe HCM (38, 55–57). 
Therefore, we focused on the cardiac effects of the Y279C mutation 
in our mice. Although normally sized at birth, LS/+ hearts became 
Figure 1
Generation of mice expressing an inducible Ptpn11 Y279C allele. (A) Structure of the Ptpn11 targeting locus and targeting construct region. 
Protein coding regions, LoxP sites, and Frt sites are shown. The arrows highlight the target positions of PCR primers used to identify homologous 
recombinants. Note that primers PLF and PRR are outside the region of homology. The expected amplicons are indicated with brackets and are 
specific to homologously recombined templates. LoxP sites are shown as black triangles; mutant LoxP511 sites are shown as white triangles. 
Their relative orientation is shown by the orientation of the triangles. FRT sites are shown as white ovals. Exons are indicated by rectangles. (B) 
Structure of locus after Flp-mediated recombination. (C) Structure of locus after Cre-mediated recombination. (D) Confirmation of correct target-
ing of ES cell clone 1F10 by PCR, revealing a 4.6-kb fragment on each correctly targeted side of the allele. M indicates molecular weight mark-
ers. (E) Germline transmission in F1 mice, as depicted by PCR, for the presence of the neo gene. (F) PCR detection strategy using LSGenofwd 
and LSR primers for detection of WT and LS/+ mice. (G) Restriction digest (HpyCH4V) of Ptpn11 exon 7 RT-PCR–derived fragment confirming 
expression of the mutant allele (full-length = 185 bp; fragment sizes = 100, 75 bp, 58 bp, 42 bp, and 10 bp [LS]; 100 bp, 75 bp, and 10 bp [WT]). 
Note that the 10-bp fragment probably comigrates with primer alone and/or contaminating RNA. PCR primers used are 721 forward/900 reverse. 
See Supplemental Table 1 for details on primers used throughout this figure. Fwd, forward; Rev, reverse.
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progressively larger than WT hearts, becoming statistically differ-
ent by 12 weeks of age (Figure 3, A and B, and data not shown). 
Analysis of H&E-stained transverse sections of 16-week-old 
hearts revealed dramatic thickening of the left ventricular free 
wall and septum (Figure 3B). Consistent with these observations, 
heart weight to body weight ratios were significantly elevated in 
hearts from 12- and 16-week-old LS/+ mice (Figure 3C). Morpho-
metric analysis of individual cardiomyocytes in reticulin-stained 
heart sections from 16-week-old mice (Figure 3D), or that of iso-
lated primary adult cardiomyocytes from 8- to 10-week-old LS/+ 
or WT mice (Figure 3E), indicated that the LS mutation did not 
affect overall cardiomyocyte number but rather significantly 
increased individual cardiomyocyte area (by ~30%), as compared 
with that of controls. Isolated cardiomyocytes also had signifi-
cantly increased cell width as opposed to length (Figure 3E), 
consistent with concentric HCM (58).
Further indicative of pathological hypertrophy in LS/+ 
hearts, we observed markedly enlarged nuclei, myofiber dis-
array, and inflammatory cell accumulation in the interstitial 
spaces between myofibers of LS/+ hearts (Figure 3F, indicated 
by arrows and magnified in inset). Electron microscopy of 
12-week-old LS/+ hearts confirmed the increase in myofibril 
size but showed no overt effects on sarcomeric structure or 
mitochondrial number or size (Figure 3G).
Table 1
μCT morphometric values from WT and LS/+ mice
Genotype	 Femur	length	(mm)	 Tibia	length	(mm)	 Skull	width/skull	length	(mm)	 Inner	canthal	distance/skull	width	(mm)
WT mice 15.66 ± 0.16 17.19 ± 0.14 0.447 ± 0.002 0.635 ± 0.003
LS/+ mice 15.07 ± 0.14A 17.02 ± 0.24 0.457 ± 0.004A 0.642 ± 0.010
Note significantly decreased femur length and increased skull width-to-length ratio. Data represent mean ± SEM (n = 5–10 mice/group); AP < 0.05, 2-tailed 
Student’s t test.
Figure 2
LS/+ mice demonstrate phenotypic abnormalities similar to those in human LS. (A) Representative photographs of en face and nose bridge 
profile (arrow) (image was brightened to enable a clear view of the facial phenotype). (B) Skeletal/chest deformity in LS/+ mice, with pectus 
carinatum superiorly (arrow) and pectus excavatum inferiorly (arrow). (C) Overall smaller body size in LS/+ mice as compared with that of WT 
mice. (D) Body length and weight are significantly less in LS/+ mice than in WT mice; n = 5–10 mice/group at each age measured. Data represent 
mean ± SEM; *P < 0.05, 2-tailed Student’s t test.
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By 52 weeks, we noted a significantly increased number of 
deaths in the LS/+ mouse cohort (Figure 4A). Hearts from the 
older LS/+ mice displayed increased myofiber disarray, enlarged 
nuclei (Figure 4B), and marked fibrosis (Figure 4C), yet their 
cardiomyocytes remained larger than those of WT (Figure 
4D). Although the precise reason(s) of excess mortality in LS/+ 
mice cannot be ascertained with certainty, these pathologic 
features strongly implicate cardiac causes (e.g., end-stage heart 
failure or arrhythmia).
To assess cardiac function and morphology more quantitative-
ly, we obtained echocardiographs of LS/+ and WT littermates at 
6, 12, 16, 20, and 52 weeks (Figure 5 and Supplemental Figure 1). 
No differences in cardiac size or function were observed at 4 to 
6 weeks of age. By 12 weeks, however, LS/+ mice had significant 
left ventricular hypertrophy, as indicated by decreased chamber 
dimension and increased posterior wall thickness compared 
with those of littermate controls. Furthermore, LS/+ mice did 
indeed transition to dilated cardiomyopathy by 52 weeks, with 
Figure 3
LS/+ mice have pathological cardiac hypertrophy. (A) Representative hearts from 16-week-old WT and LS/+ mice. (B) Transverse sections 
of WT and LS/+ hearts stained with H&E (original magnification, ×100). (C) Heart weight to body weight (HW/BW) ratios of WT and LS/+ 
mice at indicated ages (n = 5–10 mice/group at each age measured). Data represent mean ± SEM; *P < 0.05, 2-tailed Student’s t test. 
(D) Paraffin-embedded heart sections from 16-week-old WT and LS/+ mice stained with reticulin (original magnification, ×400; scale bar: 100 μm). 
The average area of WT cardiomyocytes is 2,038 ± 98.5 μm2/cardiomyocyte and that of LS/+ cardiomyocytes is 2,578 ± 115.9 μm2/ 
cardiomyocyte (P < 0.001, 2-tailed Student’s t test). Data represent mean ± SEM (200–500 cardiomyocytes/group). (E) Cardiomyocytes 
from 8- to 10-week-old WT and LS/+ hearts (original magnification, ×200). Cardiomyocyte length for WT hearts is 108.4 ± 2.6 μm and for 
LS/+ hearts is 113.5 ± 2.9 μm; cardiomyocyte width for WT hearts is 18.9 ± 0.8 μm and for LS/+ hearts is 22.4 ± 0.7 μm (P < 0.05, 2-tailed 
Student’s t test). Data represent mean ± SEM (200–500 cardiomyocytes; n = 4 mice each.). (F) H&E staining (original magnification, ×400; 
white bar: 100 μm) of paraffin-embedded longitudinal heart sections from 16-week-old WT and LS/+ mice. Note the myofiber disarray and 
increased inflammatory cells (indicated by white arrows and magnified in inset) in the interstitial spaces. (G) Scanning electron microscopy 
of cardiomyocytes (original magnification, ×4,800) from 12-week-old mice. Double arrowhead: 1 μm.
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increased diastolic dimensions and thinning of their posterior 
walls (Figure 5 and Table 2). Left ventricular function in LS/+ 
mice, as measured by ejection fraction and fractional shorten-
ing, also became impaired over time and was statistically differ-
ent from WT controls at 52 weeks (Table 2).
Cardiac hypertrophy can be secondary to pressure overload caused 
by stenotic valves. Notably, many NS and some LS patients have val-
vuloseptal abnormalities (19, 59, 60). However, LS/+ mice had no 
overt developmental valvular or septal defects, as assessed using his-
tology (data not shown). Cardiac hypertrophy also can occur as a 
consequence of hypertension; however, arterial blood pressure was 
similar in 8- to 10-week-old LS/+ and WT mice (diastolic blood pres-
sure for LS/+ mice, 89.7 mmHg, and WT mice, 84.1 mmHg; P = 0.65). 
Taken together, our data indicate that the LS-associated Ptpn11Y279C 
mutation causes HCM in mice that over time decompensates to a 
dilated cardiomyopathy with decreased cardiac function.
LS mutation causes upregulation of cardiac fetal gene expression. Fur-
ther evidence of the pathological cardiac hypertrophy in LS/+ mice 
was provided by analysis of cardiac fetal gene expression (3, 61). 
In mice, there are 2 differentially expressed cardiac myosin heavy 
chain (MHC) genes: β-MHC, which is expressed primarily during 
fetal development, and α-MHC, which is expressed primarily in 
adult myocardium (3, 61). Reexpression of β-MHC, with a signifi-
cant transition from α-MHC to β-MHC expression, is a hallmark 
for cardiac reprogramming and HCM (61). We observed signifi-
cant expression of β-MHC in LS/+ hearts compared with that in 
WT hearts (Figure 6). In addition, there was increased expression 
of other fetal genes, including atrial natriuretic factor (Anf), brain 
natriuretic peptide (Bnp), and phospholamban (Pln), and decreased 
expression of the calcium pump, SERCA2A (Figure 6), all of which 
are consistent with remodeling of the heart and HCM (61, 62).
LS mutants are catalytically impaired and show increased association 
with Shp2-binding proteins. Previously, we and others reported that 
LS mutations in SHP2, including Y279C, are catalytically defective 
and have dominant-negative effects in vitro (39–41). To examine 
the effect of Shp2-Y279C in vivo, we performed immune complex 
phosphatase assays using whole heart lysates isolated from WT 
or LS/+ mice that were either treated for 10 minutes with PBS or 
insulin (10 mU/g body weight). As an additional (positive) control 
for the sensitivity of our PTP assay, we included lysates from simi-
larly treated D61G/+ mice (43), which express a catalytically acti-
vated, NS-associated Ptpn11 allele (Figure 7A). Whereas WT hearts 
had low basal activity that could be induced by insulin stimula-
tion, LS/+ hearts had an approximately 50% reduction in Shp2 
Figure 4
Decreased survival in LS/+ mice. (A) Kaplan-Meier curve of WT ver-
sus LS/+ mice (n = 5–8 mice per group at each age point). Note sig-
nificantly decreased survival in LS/+ mice at 12 months. *P < 0.05, 
log-rank test. (B) H&E-stained sections (original magnification, ×400; 
scale bar: 100 μm) depicting myofiber disarray and enlarged nuclei 
in 52-week-old LS/+ hearts compared with WT hearts. (C) Masson-
Trichrome stain of paraffin-embedded longitudinal heart sections from 
WT and LS/+ mice reveals marked fibrosis in LS/+ hearts at 52 weeks 
of age (original magnification, ×400). Fibrous tissue is stained in blue 
and magnified in inset. (D) Reticulin stain of paraffin-embedded heart 
sections from 52-week-old WT and LS/+ mice (original magnification, 
×400), showing enlarged LS/+ cardiomyocytes.
Figure 5
LS/+ mice have HCM that progresses to chamber dilation. Represen-
tative echocardiographs of WT and LS/+ mice at 12 to 14 weeks of 
age and 52 weeks of age, respectively. Two-headed arrows indicate 
left ventricle chamber size. Note that at 12 weeks, LS/+ hearts have 
small chamber dimensions compared with those of WT controls; at 52 
weeks, LS/+ hearts have increased chamber dimensions and have 
dilated/decompensated compared with those of WT controls.
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phosphatase activity, in accord with the heterozygous expression 
of the Ptpn11Y279C allele. There also was no increase in Shp2 activ-
ity after insulin stimulation, consistent with a dominant-negative 
effect of the LS mutant. By contrast, D61G/+ heart lysates had 
dramatically enhanced basal and insulin-stimulated Shp2 activity. 
Similar results were obtained when liver lysates were used as the 
source for Shp2 (data not shown). Together, these data confirm 
that Shp2 LS mutations are catalytically defective and have domi-
nant-negative effects in vivo.
Previous in vitro data suggest that LS mutations preferential-
ly adopt the open conformation (39, 41). Consistent with this 
notion, we observed increased basal as well as 
IGF-1–induced association of Shp2 with IRS-1 
(Figure 7B) and Gab1 (data not shown) in LS/+ 
cardiomyocytes compared with that in WT cells. 
These data validate our previous results (39) and 
suggest how LS mutations might function as 
dominant negatives.
Agonist-evoked Erk activation is impaired in LS/+ 
mice. Multiple types of receptors contribute 
to the survival and growth of cardiomyocytes, 
and SHP2 is required for normal activation of 
the RAS/MAPK pathway downstream of most, 
if not all, RTKs, cytokine receptors, GPCRs, 
and integrins. To assess the functional conse-
quences of LS mutations on Erk activation, we 
isolated whole hearts from LS/+ or WT mice 
before or 10 minutes after i.p. injection of PBS 
(vehicle) or insulin. Although we observed no 
significant difference in basal Erk1/2 activity 
between the LS/+ and WT hearts, there was sig-
nificant attenuation in Erk1/2 activation after 
insulin stimulation in LS/+ hearts, compared 
with WT controls (Figure 8, A and B). Consis-
tent with these data, Erk1/2 activation also was 
decreased in isolated primary cardiomyocytes 
from 8-week-old LS/+ mice stimulated with 
RTK (IGF-1, EGF-1), GPCR (angiotensin II), or 
cytokine (IL-6) agonists (Figure 8C). Togeth-
er, these data reveal an intrinsic defect in Erk 
pathway activation in LS/+ cardiomyocytes. 
Moreover, these findings contrast with the 
effects of an NS-associated, kinase-activating Raf1 mutation in 
mice, which, as illustrated in the accompanying manuscript (63), 
develop cardiac hypertrophy due to excessive Ras/Mapk activity 
(see Discussion).
The Akt/mTor pathway is hyperactivated in LS/+ hearts. Shp2 also plays 
a significant, although complex, role in PI3K/AKT pathway regula-
tion (64–66). Notably, basal as well as insulin-induced Akt473 phos-
phorylation was increased in LS/+ hearts (Figure 9, A and B). Basal 
and agonist-induced Akt473 phosphorylation also was enhanced in 
IGF-1–stimulated (Figure 9, C and D) or IL-6–stimulated (data not 
shown) primary cardiomyocytes from LS/+ mice, compared with 
Table 2
Anatomic and functional parameters, as assessed by echocardiography, in WT and LS/+ mice at the indicated ages
	 4–6	weeks	 12–14	weeks	 52	weeks	
	 WT	 LS/+	 WT	 LS/+	 WT	 LS/+
BW (g) 19.9 ± 1.0 18.9 ± 0.7 24.9 ± 0.5 22.6 ± 1.1A 35.5 ± 4.5 32.7 ± 1.8
HR (bpm) 658 ± 21.1 691 ± 26.9 672 ± 25.2 648 ± 25.3 715 ± 29.1 668 ± 27.8
LVPW-th (mm) 0.93 ± 1.07 1.15 ± 0.13 1.04 ± 0.09 1.58 ± 0.07A 0.85 ± 0.04 0.61 ± 0.06A
LVID-d (mm) 2.34 ± 0.16 2.16 ± 0.10 2.70 ± 0.23 1.86 ± 0.24A 2.83 ±.086 3.68 ± 0.15A
FS% 56.65 ± 2.29 55.23 ± 2.28 56.37 ± 2.33 61.40 ± 2.35 50.99 ± 0.23 36.69 ± 1.94A
n 8 8 8 8 5 5
Note the increased posterior wall thickness, smaller left ventricular chamber dimension, and increased fractional shortening (consistent with enhanced 
contractility) in 12- to 14-week-old LS/+ hearts compared with that in WT hearts. By 52 weeks, LS/+ hearts have thinned and dilated, with functional decom-
pensation, as indicated by decreased fractional shortening. Note that the fractional shortening calculation includes the papillary muscle. No significant differ-
ences were seen in any parameters in 4- to 6-week-old LS/+ mice compared with WT littermates. Data represent mean ± SEM; AP < 0.05, 2-tailed Student’s  
t test (see Supplemental Figure 1 for specific P values). Hr, heart rate; LVID-d, left ventricular chamber dimension in diastole; FS%, fractional shortening.
Figure 6
LS/+ mice upregulate expression of cardiac fetal genes. Total RNA from WT and LS/+ 
mice (n = 4–6 of each genotype) of the indicated ages was used to perform quantitative 
RT-PCR (each sample in triplicate). The ratio of ΔΔCT was analyzed using GAPDH as a 
control. Data represent mean ± SEM; *P < 0.01, 2-tailed Student’s t test. Note the signifi-
cant difference in cardiac fetal gene expression in LS/+ and WT hearts of the same age.
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that in WT controls. The mTor pathway, a downstream target of 
Akt, was hyperactivated in LS/+ hearts, even under basal conditions, 
as indicated by elevated levels of Tsc2 phosphorylation at S1462, an 
Akt phosphorylation site, and enhanced p70S6K phosphorylation 
(Figure 9C). These data suggested that LS mutants might cause 
HCM, at least in part, via increased Akt/mTor activation.
The LS/+ mutation impairs multiple downstream signaling pathways 
involved in HCM. We next analyzed the status of other pathways 
implicated in cardiac hypertrophy in our LS/+ mice. Fak was 
recently shown to be associated with Shp2 in neonatal rat ven-
tricular myocytes (NRVMs). Depletion of Shp2 by siRNA in 
these cells increased the phosphorylation of Fak, Akt, Tsc2, 
and S6 kinase and induced cellular hypertrophy, suggesting 
that Shp2 can control cardiomyocyte size by downregulation 
of a pathway that involves Fak and mTor signaling (67). Nota-
bly, Fak phosphorylation (at Y397) was significantly elevated 
in LS/+ heart lysates, as compared with that in WT heart lysates 
(Figure 10, A and B). These data raise the possibility that the 
elevated levels of Akt phosphorylation in LS/+ hearts may be 
due to increased Fak activity and that Fak might be a substrate 
for Shp2 in cardiomyocytes (see Discussion).
To assay stress-mediated signaling pathways in LS/+ hearts, we 
measured Jnk1/2 and Stat3 phosphorylation. Jnk1/2 were consti-
tutively activated in LS/+ cardiomyocytes, whereas in WT cardio-
myocytes, Jnk1/2 phosphorylation was induced only after IGF-1 
(Figure 10C) or IL-6 (data not shown) stimulation. Stat3 phosphor-
ylation also was basally upregulated in LS/+ cardiomyocytes, and its 
phosphorylation increased further after IGF-1 (Figure 10D) or IL-6 
(data not shown) stimulation. Together, these data indicate that LS 
mutants affect several important cellular signaling pathways in the 
heart. The combined effects of some or all of these signaling abnor-
malities presumably lead to the cardiac defects associated with LS.
LS/+ cardiomyocytes respond to rapamycin treatment. Although LS/+ 
mice have alterations in several signaling pathways, the known role 
of the TOR pathway in the control of cell size (68, 69) and the abil-
ity of Y279C mutant to enhance Akt/mTor activity, suggested that 
this pathway might be required for HCM pathogenesis in LS/+ 
mice. To begin to test this possibility, we first asked whether reduc-
tion of mTorc1 activity could ameliorate the cellular abnormalities 
in LS/+ cardiomyocytes. Primary cardiomyocytes from WT or LS/+ 
mice were treated with rapamycin (0.02 μM) for 12 hours. After 
this treatment, the size of the LS/+ cardiomyocytes was indeed sig-
nificantly reduced (Supplemental Figure 2). By contrast, there was 
no effect of Jnk or Stat inhibitors on overall LS/+ cardiomyocyte 
cell surface area (Supplemental Figure 2). These data suggested 
that, while multiple signaling abnormalities might contribute to 
the cardiac phenotype in LS/+ mice, excessive Akt/mTOR signaling 
is an essential contributor to pathologic cardiac hypertrophy.
We next asked whether we could normalize the cardiomyocyte 
defects in vivo. We administered daily i.p. injections of either vehi-
cle or rapamycin (2 mg/kg body weight) to 8-week-old WT or LS/+ 
mice for 4 weeks. At the onset of this treatment period, LS/+ heart 
size was not significantly different from that of WT heart size (data 
not shown, but see Supplemental Figure 1 for reference). When the 
mice reached 12 weeks of age (a time at which significant hypertro-
phy is evident in LS/+ mice; see Figure 3), we isolated primary car-
diomyocytes from vehicle- and rapamycin-treated mice and quan-
tified their area 2 hours after plating. Remarkably, cardiomyocytes 
Figure 7
LS mutants are catalytically impaired and show increased binding to IRS-1. (A) WT, DG/+, and LS/+ 8- to 10-week-old mice were treated for 10 
minutes with PBS or insulin (10 mU/g body weight). Hearts were isolated and lysed, and Shp2 immune complex PTP assays were conducted 
using pNPP as a substrate. The bottom panel shows comparable recovery of immunoprecipitated Shp2. Experiments were performed in trip-
licate (n = 4–6 animals per group). Data represent mean ± SEM; *P < 0.05, †P < 0.001, ‡P < 0.01. All P values were derived from ANOVA with 
Bonferroni post-test when ANOVA was significant. (B) Primary cardiomyocytes isolated from 8- to 10-week-old WT or LS/+ mice were either left 
unstimulated or were stimulated for 15 minutes with IGF-1 (10 nM). Lysates from these cells were immunoprecipitated with anti–IRS-1 antibodies 
and immunoblotted with anti-Shp2 or anti–IRS-1 antibodies, as indicated, to detect complex formation. The bottom panel represents quantifica-
tion of immunoprecipitated Shp2 normalized to total IRS-1 levels from the above experiment. Note increased IRS-1/Shp2 complex formation in 
LS/+ cardiomyocytes as compared with that in WT cardiomyocytes, even in the absence of IGF-1 stimulation.
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isolated from rapamycin-treated LS/+ mice had significantly 
decreased cell size as compared with that of vehicle-treated LS/+ 
cells (Figure 11A). By contrast, rapamycin (at least at this dose) had 
little/no effect on the size of WT cardiomyocytes; consequently, 
the sizes of rapamycin-treated LS/+ and WT (untreated or rapamy-
cin-treated) cardiomyocytes were similar (Figure 11B).
As expected, rapamycin treatment reduced the phosphorylation 
of the downstream mTorc1 target, p70S6 kinase (Figure 11C), but 
did not affect Erk, JNK, or Stat3 activation (Supplemental Figure 
3). The phosphorylation of Akt on S473, an mTorc2 phosphoryla-
tion site, also was reduced, as was the phosphorylation of GSK-3α 
on its Akt site, Ser21. Although rapamycin only inhibits mTorc1 
directly, chronic rapamycin administration has been reported to 
sequester Tor into the (inhibited) mTorc1 complex, resulting in 
inhibition of both mTor complexes (70). Notably, when we discon-
tinued our daily injections of rapamycin (see below) and adminis-
tered only a once a week dose of rapamycin, we reversed this effect 
and normalized Akt activity (data not shown).
Rapamycin treatment normalizes HCM in LS/+ mice. After 4 weeks 
of treatment, hearts from rapamycin-treated LS/+ mice but not 
vehicle-treated LS/+ mice showed a trend toward decreased size, as 
measured by heart weight to body weight ratios, but this difference 
did not reach statistical significance (data not shown). Compared 
with vehicle-treated LS/+ mice, rapamycin-treated mice did show 
a substantial reduction in left ventricular posterior wall thickness 
(LVPW-th) to values indistinguishable from their WT littermates. 
However, chamber dimensions remained abnormally small in 
rapamycin- and vehicle-treated LS/+ mice.
These findings indicated that even short-term rapamycin treatment 
had some therapeutic efficacy for LS-associated HCM and suggested 
that prolonging the treatment period might be even more beneficial. 
Therefore, we treated another cohort of WT and LS/+ mice daily with 
either vehicle or rapamycin (2 mg/kg body weight i.p.) for 4 weeks, 
followed by an additional 4 weeks of weekly injections of the same 
dose. A similar protocol has been used to analyze the effects of mTor 
inhibition in mouse models of polycystic kidney disease (71) and 
tuberous sclerosis complex disorder (72). Remarkably, after 8 weeks 
of rapamycin treatment, the gross size of LS/+ hearts appeared normal 
(Figure 12A). LS/+ cardiomyocyte area was reduced, compared with 
that of vehicle-treated LS/+ cells (Figure 12, B and C), to a level com-
parable to that of WT control cardiomyocytes. Heart weight to body 
weight ratios of rapamycin-treated LS/+ mice decreased significantly, 
also becoming indistinguishable from control values (Figure 12D). 
Furthermore, echocardiographic analysis showed normalization of 
LVPW-th and left ventricular chamber diameter (Figure 12, E and F).
Rapamycin treatment reverses HCM in LS/+ mice. The above experi-
ments indicated that rapamycin treatment could prevent the devel-
opment of HCM in LS/+ mice. To test whether rapamycin also 
could reverse established hypertrophy, we treated a new cohort 
of LS/+ mice with rapamycin, beginning at 12 weeks of age, when 
these mice already have apparent HCM (see Figure 3). WT or LS/+ 
mice were treated daily with vehicle or rapamycin (2 mg/kg body 
weight i.p.) for 4 weeks, followed by an additional 4 weeks of week-
ly injections of the same dose. Serial echocardiographic analysis at 
the 4- and 8-week time points (16- and 20-week-old mice, respec-
tively) showed normalization of the LVPW-th and left ventricular 
chamber diameter (Figure 13, A and B). Furthermore, there was 
significant reversal of the abnormal fetal gene expression profile 
of hearts from rapamycin-treated LS/+ mice (Figure 14). Together, 
these data show, that treatment with rapamycin can reverse HCM 
in LS/+ mice and suggest that rapamycin might be an effective, 
targeted therapy for HCM in human LS patients.
Figure 8
Agonist-evoked Erk MAPK activation is impaired in LS/+ mice. (A) Whole heart lysates from either unstimulated or 10-minute insulin-stimulated 
(10 mU/g body weight) WT and LS/+ mice (8- to 10-week-old) were harvested, lysed, and immunoblotted with anti-phospho–Erk1/2 antibodies. 
The blot was reprobed with anti-Erk1/2 antibodies as a loading control. Each lane represents an individual animal. (B) Quantification of data 
collected from 4–6 animals for each group, each derived from 3 different experiments. *P < 0.01, ANOVA plus Bonferroni post-test when 
ANOVA was significant. Note the significant difference between basal and insulin-stimulated Erk activity of WT heart lysates, but the lack of 
significant differences between Erk activity in either basal WT and LS/+ hearts or in basal and insulin-stimulated LS/+ hearts, respectively. (C) 
Primary cardiomyocytes isolated from 8-week-old WT and LS/+ mice were collected, cultured overnight, and then either left unstimulated or 
stimulated for the indicated times with IGF-1 (10 nM), EGF (25 ng/ml), angiotensin II (100 nmol/l), or IL-6 (10 ng/ml). Data are representative of 
n = 3 independent experiments. Cell lysates were immunoblotted with anti-phospho–Erk1/2 antibodies, and then membranes were reprobed 
with anti-Erk1 antibodies to control for loading.
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 121   Number 3   March 2011 1035
Discussion
To study LS pathogenesis, we generated inducible knockin mice har-
boring the Ptpn11 mutation Y279C. Similar to the human LS phe-
notype, LS/+ mice have short stature, craniofacial dysmorphia, and 
skeletal abnormalities (20, 31, 55). In addition, several lines of evi-
dence indicate that LS/+ mice have pathological cardiac hypertrophy: 
(a) their hearts are enlarged, and they show increased heart weight to 
body weight ratios; (b) LS/+ cardiomyocytes show myofiber disarray, 
inflammatory cells within the myocardial interstitium, and fibrosis; 
(c) cardiac fetal gene expression is reactivated in LS/+ mice, includ-
ing a shift from α-MHC to β-MHC gene expression; (d) LS/+ cohorts 
have an increased death rate compared with that of WT mice; and 
(e) LS/+ mice transition from hypertrophy to dilation by 52 weeks 
of age, and cardiac function declines concomitantly. Biochemically, 
LS/+ mutant hearts and/or cardiomyocytes show enhanced binding 
of Shp2 to IRS-1, decreased phosphatase activity, and abrogated ago-
nist-evoked Erk activation, consistent with previous reports that LS 
mutants have dominant-negative effects in vitro (39–41). By contrast, 
Akt/mTor signaling is enhanced significantly in LS/+ hearts, as well 
as in cardiomyocytes, consistent with recent findings on fibroblasts 
isolated from LS patients (73), and there is increased phosphoryla-
tion of Stat3 and Jnk1/2, 2 other signaling molecules implicated in 
cardiomyopathy (74, 75). Although we cannot exclude the possibility 
that these other signaling pathways contribute to HCM in vivo (i.e., 
in LS/+ mice themselves), inhibiting the mTor pathway by rapamycin 
treatment completely normalized and reversed the LS cardiac defects, 
both in vitro and in vivo. Together, these data directly implicate exces-
sive Akt/mTor activity in LS pathogenesis and suggest that therapeu-
tic efficacy of rapamycin should be evaluated in LS patients.
Some features in LS/+ mice are reminiscent of the phenotype of 
mice expressing NS-associated gain-of-function Ptpn11 mutations 
(43, 76, 77) and of the abnormalities seen in NS patients (78). Germ-
line PTPN11 mutations cause NS and LS, and both NS and LS are 
part of the family of autosomal dominant RASopathies caused by 
mutations in different components of the RAS/RAF/MEK/ERK 
MAPK pathway (29, 30). Not surprisingly, each of these disorders 
shares some phenotypes, albeit with varying degrees of penetrance. 
Yet, each RASopathy also has clinically distinguishable features. 
Mouse models recapitulated some of these differences. For example, 
2 parallel studies on knockin mice expressing the NS-associated Sos1-
E846K (79) and Raf1-L613V (63) mutations, respectively, show that 
mutations in different genes along the same pathway yield different 
phenotypes: Sos1-E846K/+ mice develop HCM with incompletely pen-
etrant aortic stenosis, whereas the Raf1-L613V/+ mice develop HCM 
with normal valvuloseptal development. Even distinct mutations in 
the same RASopathy gene can result in distinguishable phenotypes, 
as shown for Ptpn11 mutations with different degrees of Shp2 acti-
vation (43, 76, 77). Indeed, differential expression of the individual 
causal mutants, and/or their activity, localization, and feedback regu-
lation in different cell/tissue types, probably accounts for the variable 
severity and/or phenotype in each RASopathy.
Mutations associated with different RASopathies also have dis-
tinct effects in mice. Biochemical, cell biological, and genetic stud-
ies indicate that the PTPN11 alleles associated with NS are hyper-
morphs that enhance Erk pathway activation (44). Given that 
knockin models of activated Sos1 (79) and Raf1 (63) each show 
HCM, whereas absence of Ptpn11 in cardiomyocytes causes dilated 
cardiomyopathy (16), one might expect NS-associated PTPN11 
Figure 9
Activation of the Akt/mTOR pathway is enhanced in LS/+ hearts and cardiomyocytes. (A) Whole heart lysates from either unstimulated or 
10-minute insulin-stimulated (10 mU/g body weight) WT and LS/+ mice (8 weeks old) were harvested, lysed, and immunoblotted with anti-
phospho–Akt473 antibodies, followed by anti-Akt antibodies to control for loading. Each lane represents an individual animal. The dividing line 
represents grouping of images from the same gel. (B) Quantification of data collected from 4–6 animals from each group, derived from 3 inde-
pendent experiments. *P < 0.001, †P < 0.05, ‡P < 0.05. All P values were derived from ANOVA plus Bonferroni post-test when ANOVA was 
significant. (C) Primary cardiomyocytes from either unstimulated or IGF-1 stimulated (10 nM) WT and LS/+ mice (8 to 10 weeks old) were lysed 
and immunoblotted with anti-phospho–Akt473, Tsc21462, or p70S6K antibodies, as indicated, followed by anti-Akt antibodies to control for loading. 
(D) Quantification of Akt phosphorylation, derived from 3 independent experiments. *P < 0.05, †P < 0.001, ‡P < 0.001. All P values were derived 
from ANOVA plus Bonferroni post-test when ANOVA was significant.
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mutations to cause HCM. Yet, HCM is rare in NS patients with 
PTPN11 mutations (80–82). Moreover, knockin mice for the NS 
allele Ptpn11 D61G exhibit valvuloseptal defects similar to those in 
NS but no evidence of HCM (43). On the other hand, LS is caused 
almost exclusively caused by catalytically impaired PTPN11 muta-
tions (39, 40), and HCM is the most common cardiac abnormal-
ity in this syndrome (34, 37, 83). Our Ptpn11Y279C knockin mice 
show that the predominant cardiac manifestation of LS, HCM, 
is a direct and specific consequence of expression of catalytically 
impaired mutants of Ptpn11 (rather than, for example, the effects 
of different modifiers in the human population).
The molecular basis for the events that lead to hypertrophic 
responses in the heart are confounding and complex. As Shp2 is 
a critical upstream regulator in multiple RTK, cytokine, GPCR, 
and integrin-mediated signaling pathways (84), Shp2 mutations 
might be expected to have several effects in the heart. Indeed, LS/+ 
cardiac lysates show enhanced binding of Shp2 to IRS-1, decreased 
phosphatase activity, and abrogated agonist-evoked Erk activa-
tion, consistent with our previous findings that LS mutants have 
dominant-negative effects on the Erk/Mapk pathway (39). Nota-
bly, 2 previous studies reported that LS mutants evoke increased 
Erk activation. Expression of the LS mutants Y279C or T468M in 
Drosophila resulted in ectopic wing veins and a rough eye pheno-
type, characteristic of increased Erk activity in these tissues, and 
genetic analysis of enhancers and suppressors also was consistent 
with hypermorphism of the Erk pathway in these mutant flies 
(47). Furthermore, in a very recent study, induced pluripotent 
stem cells (iPSCs) from LS patient-derived fibroblasts showed 
higher basal p-ERK levels compared with those of control iPSCs 
(85). By contrast, LS mutants of shp2 were found to have domi-
nant-negative effects when expressed in Zebrafish (48, 49), consis-
tent with our findings that basal Erk activation is unchanged and 
agonist-evoked activation is abrogated in LS/+ mice. The reasons 
for these discrepancies are unclear but might 
relate to species differences, cell-type specific-
ity, and/or the effects of overexpression.
Regardless, our data are inconsistent with 
the hypothesis that excessive Erk activity 
causes HCM in LS/+ mice (and, by inference, in 
humans). Instead, our results suggest that the 
excessive Akt/mTor pathway activity is critical 
for the cardiac pathogenesis in LS (Supplemen-
tal Figure 4). Our biochemical studies, which 
are consistent with recent work on fibroblasts 
isolated from LS patients (73), showed increased 
Akt activation, as exemplified by increased 
Akt473 phosphorylation and, more importantly, 
increased phosphorylation of Tsc2 and GSK-3α 
on known Akt phosphorylation sites. This, in 
turn, leads to increased mTor activity, as indi-
cated by increased phosphorylation of the mTor 
substrate, p70S6K (Supplemental Figure 4).
Previous pharmacological studies have 
shown that treatment of cardiomyocytes with 
rapamycin could inhibit the hypertrophic 
response evoked by stimulation with various 
agonists (86–89). Rapamycin also attenuates 
or reverses pressure overload- or constitutive-
ly active Akt-induced cardiac hypertrophy (87, 
90, 91), supporting our findings that there is 
a potential regulatory role for mTor in HCM. By contrast, a recent 
study of transgenic mice with cardiomyocyte-specific expression 
of constitutively active or kinase-dead mutants of mTor, respec-
tively, showed no overt cardiac phenotype (92). There are several 
possible explanations for this apparent discrepancy with our 
findings. First, in the above study, the transgenes were expressed 
only in cardiomyocytes, whereas in LS/+ mice, mutant Ptpn11 
was expressed ubiquitously. Recent data indicate the cardiac 
fibroblasts can also contribute to HCM (93–96), and it is conceiv-
able that both cardiomyocyte and cardiac fibroblast signaling 
abnormalities contribute to HCM in our model. Second, trans-
gene expression of the kinase-active and kinase-dead mTor was 
induced by αMHC-Cre expression, which expresses postnatally in 
the mouse (97); conceivably, aberrant mTor signaling must occur 
during development to cause HCM. Third, the extent to which 
transgenes that drive expression of kinase-dead and kinase-active 
mTor represent endogenous activation/inactivation of the mTor 
pathway, as in our LS/+ mice, is unclear. For example, kinase-active 
or kinase-dead mTor would affect mTorc1 and mTorc2. Rapamy-
cin, by contrast, inhibits only mTorc1. Last, as discussed further 
below, although our experiments using primary cardiomyocytes 
argue against roles for elevated JNK and/or Stat3 in cardiac hyper-
trophy in LS/+ mice (Supplemental Figure 3), we cannot (and do 
not) exclude roles for these other signaling pathways in the whole 
animal context. Overall, we believe that our system, in which the 
mTor pathway is activated under endogenous promoter control by 
the mouse analog of a human disease-associated PTPN11 mutant, 
is a more physiologically relevant system for analyzing the role of 
mTor pathway elevation in LS.
Most importantly, our data indicate that the biochemical abnor-
malities in LS/+ hearts have functional consequences, as illustrated 
by the dramatic effects of rapamycin on the cardiac phenotype of 
LS/+ mice. After 8 weeks of rapamycin treatment, the gross size 
Figure 10
Multiple cardiac signaling pathways are affected in LS/+ mice. (A) Whole heart lysates from 
WT and LS/+ 8-week-old mice were harvested, lysed, and immunoblotted with anti-phos-
pho-FAK397 antibodies. The blot was reprobed with total anti-Fak antibodies as a loading 
control. Each lane represents an individual animal. (B) Quantification of data collected from 
4–6 animals from each group, derived from 3 independent experiments. *P < 0.05, 2-tailed 
Student’s t test. (C and D) Primary cardiomyocytes isolated from 8- to 10-week-old WT and 
LS/+ mice were collected, cultured overnight, and then either left unstimulated or stimulated 
for the indicated times with IGF-1 (10 nM). Cells were lysed and immunoblotted with (C) 
anti-phospho-JNK1/2 or (D) anti-phospho-Stat3 antibodies. Blots were reprobed with anti-
JNK or anti-Stat3 antibodies, as indicated, to control for loading. Data are representative of 
n = 3 independent experiments.
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of LS/+ hearts appeared normal, and cardiomyocyte area, heart 
weight to body weight ratios, LVPW-th, and left ventricular cham-
ber diameter all were restored to normal levels. At the molecular 
level, as expected, chronic rapamycin treatment reduced the phos-
phorylation of Tsc2 and p70S6 kinase. In addition, the phos-
phorylation of Akt on S473, an mTorc2 phosphorylation site, was 
reduced, as was the phosphorylation of GSK-3α on its Akt site, 
Ser21. Although rapamycin only inhibits mTorc1 directly, chronic 
rapamycin administration can sequester mTor into the (inhibited) 
mTorc1 complex, thereby resulting in inhibition of both mTor 
complexes (70). Hence, chronic rapamycin treatment might exert 
its beneficial effects via Akt inhibition as well. However, when we 
discontinued daily injections of rapamycin and administered it to 
LS/+ mice only once a week, Akt activity was restored to WT levels 
(data not shown) and their hearts appeared normal (see Figure 12, 
F and G). Consequently, we suspect that rapamycin’s beneficial 
effects are mediated primarily via mTor inhibition.
Rapamycin is best known as an immunosuppressive drug (98). 
Nevertheless, it also has been used for other purposes, both in 
animal models and humans. For example, previous studies have 
demonstrated its efficacy in the treatment of cardiac hypertro-
phy in spontaneously hypertensive rats (99) and in reducing 
pressure overload-induced hypertrophy in mice (91, 100). Rapa-
mycin also has proven beneficial for treatment of polycystic kid-
ney disease in mice (101, 102), a therapy that has moved to clini-
cal trials (103, 104), and a rapamycin analog is now approved 
for the treatment of renal cancer (105). Taken together, our data 
argue strongly that clinical trials of rapamycin or a rapamycin 
analog be considered for the treatment of LS-associated HCM.
Excessive Akt/mTor activity in LS/+ mice is most likely due to 
increased PI3K activation; indeed, Shp2 can have positive (or nega-
tive) effects on the PI3K/Akt pathway, depending on the specific 
upstream pathway and/or the cellular context (66). There are at least 
2 potential ways in which LS mutants might cause increased PI3K 
activation. First, previous work has suggested that Shp2 can dephos-
phorylate the binding sites for PI3K on Gab1 (66, 106). Recent stud-
ies of the effects of Ptpn11 deletion in the liver suggest that Shp2 also 
dephosphorylates the PI3K binding sites on IRS-1/2 (107). Alterna-
tively, or in addition, excessive Fak activity may also play a role in 
increased PI3K activation in LS/+ hearts. A recent study showed that 
Fak is associated with Shp2 in NRVMs. Moreover, depletion of Shp2 
by siRNA increased phosphorylation of Fak, Akt, Tsc2, and S6 kinase 
and induced hypertrophy of NRVMs (67). Indeed, heart lysates from 
our LS/+ mice had elevated Fak phosphorylation as well. Further 
studies will be required to determine whether, in fact, LS/+ hearts/
cardiomyocytes have increased PI3K activity and, if so, whether either 
(or both) of the above mechanisms is responsible for this increase.
While it is true that the PI3K/Akt pathway plays an important 
role in regulating cardiac homeostasis/adaptive hypertrophy 
(108), the mechanisms are controversial. Mice expressing a car-
diac-specific constitutively active mutant of the PI3K 110α sub-
unit developed substantial physiological hypertrophy but did not 
transition into pathological hypertrophy (109). Conversely, cardiac 
expression of a dominant-negative PI3K p110α catalytic subunit 
impaired physiological hypertrophy (110, 111), whereas the PI3K 
p110γ subunit was shown to be required for maladaptive hypertro-
phy (111, 112). On the other hand, short-term activation of Akt1 
promotes cardiomyocyte viability and reverses hypertrophy, while 
Figure 11
LS/+ cardiomyocytes respond to rapamycin treatment. (A) Photomicrograph of primary cardiomyocytes isolated from vehicle-injected WT, 
vehicle-injected LS/+, or rapamycin-injected LS/+ mice after 4 weeks of daily injections. Original magnification, ×200. (B) Quantification of the dif-
ferences in area between vehicle- or rapamycin-treated WT and LS/+ cardiomyocytes (200–500 cells per group). Note the significant difference 
in total area between WT and LS/+ cardiomyocytes. Rapamycin had little/no effect on WT cardiomyocyte cell size. Results are the mean ± SEM. 
*P < 0.001, 2-tailed Student’s t test. (C) Inhibiting mTorc1 activity rescues aberrant LS/+ signaling. Whole heart lysates from vehicle-treated WT, 
vehicle-treated LS/+, and rapamycin-treated LS/+ mice after 4 weeks of daily injections were harvested, lysed, and immunoblotted with anti-
phospho–Akt473, –GSK-3α (Ser21), –Tsc21462, and –p70S6K antibodies, followed by anti-Akt antibodies to control for loading, respectively. Note 
that rapamycin treatment reversed the Akt/mTor pathway signaling defects associated with LS/+ mutation. rapa, rapamycin.
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chronic Akt1 activation induces extensive cardiac hypertrophy, 
with severe contractile dysfunction and massive interstitial fibrosis 
(113, 114). These findings indicate that the PI3K/Akt pathway is 
highly complex, with differential roles in regulating cardiac hyper-
trophy. Clearly, further studies are needed to better elucidate the 
mechanism(s) for these signaling-specific differences.
Indeed, although our data clearly implicate excessive Akt/
mTor activity in LS cardiac pathogenesis, we cannot and do 
not exclude the possibility that other signaling abnormali-
ties contribute either to the initial hypertrophic phase or to 
the ultimate dilation of LS hearts. For example, the inability 
of LS mutants to activate Erk in response to agonist stimula-
Figure 12
Rapamycin normalizes HCM in LS/+ mice. (A) H&E-stained longitudinal sections of hearts from WT and LS/+ mice. Note normalization of 
hypertrophy in LS/+ hearts after rapamycin treatment (original magnification, ×100). (B) Reticulin stain of paraffin-embedded heart sections from 
16-week-old WT and LS/+ mice (original magnification, ×400). (C) Quantification of average area (in μm2) of cardiomyocytes (200–500 cells 
counted/group) from WT or LS/+ cardiomyocytes isolated from mice that were either vehicle- or rapamycin-treated (2 mg/kg body weight) daily 
by i.p. injection for 4 weeks, then weekly for 4 weeks; see Results and Methods for details. Results are shown as the mean ± SEM. *P < 0.05, 
†P < 0.05. (D) Heart weight to body weight ratios of WT and LS/+ mice with vehicle- or rapamycin-treatment, as indicated. *P < 0.05, †P < 0.001. 
(E) Representative echocardiographs from 16-week-old vehicle-treated WT, vehicle-treated LS/+, or rapamycin-treated LS/+ mice. Two-headed 
arrows indicate left ventricle chamber size. (F) Anatomic and functional parameters of 12- and 16-week-old WT, LS/+, and LS/+ rapamycin-
treated mice, as assessed by echocardiography, either after 4 weeks (measured at 12 weeks of age) or after 4 weeks of daily i.p. injections, 
followed by 4 weeks of weekly (measured at 16 weeks of age) i.p. injections. LVID-d, left ventricular chamber dimension in diastole. *P < 0.001 
denotes significance between the vehicle-treated 16-week-old LS/+ mice and the LS/+ rapamycin-treated mice. All P values in C, D, and F were 
derived from ANOVA and Bonferroni post-test when ANOVA was significant.
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tion might contribute to the eventual transition to dilation in 
the LS/+ mice, perhaps in tandem or in parallel with increased 
Jnk and/or Stat3 activities. Jnk and/or Stat3 themselves might 
be important contributors to hypertrophy in LS; increased Jnk 
activity is associated with development of cardiac hypertrophy 
(74), and Stat3 phosphorylation is significantly upregulated 
in the failing heart with dilated cardiomyopathy (75). Interest-
ingly, however, inhibition of Jnk and Stat3 had little effect on 
overall cardiomyocyte cell surface area in vitro (Supplemental 
Figure 2). Given that these inhibitors lack specificity and have 
poor bioavailability, evaluation of the overall contribution of 
aberrant Jnk and Stat activity to HCM in LS/+ mice (in vivo) 
will require genetic approaches. However, it will be important 
to clarify the role of these other signaling abnormalities in LS 
pathogenesis, as they may provide additional targets for thera-
peutic intervention.
In summary, our data support the conclusion that exces-
sive Akt/mTOR activity is essential for the development and 
maintenance of HCM in LS, and we identify a potential effec-
tive treatment for the reversal of HCM in LS patients. Attention 
has naturally focused on the ERK/MAPK pathway in explaining 
the pathogenesis of RASopathies. However, our data argue that 
different RASopathies can have complex and distinct effects on 
cellular signaling pathways. Knowledge of the detailed effects 
of these mutations on molecular and cellular signaling is essen-
tial for a more rational and personalized approach to therapy 
for these disorders.
Methods
Generation of LS/+ mice
The targeting construct was generated using recombineering methodology 
as developed by Liu et al. (51). Our strategy used unidirectional Cre-medi-
ated inversion of a duplicated mutant (Y279C) exon, permitting expression 
of the WT protein in the absence of Cre and the mutant product after Cre 
exposure. Briefly, a 9.3-kb fragment (based on the C57BL/6 genome, build 
NCBIM37) of the mouse Ptpn11 gene containing exons 7–9 (extending 4,871 
bp upstream of exon 7 and 2,148 bp downstream of exon 9) was subcloned 
by recombineering from the bacterial artificial chromosome, bMQ-311k06 
(Geneservice), into a plasmid containing a TK selection cassette. A loxP 
site was inserted by recombination 371 bp upstream of exon 7. Exon 7 was 
amplified by PCR (761-bp fragment extending 371 bp upstream and 294 
bp downstream), and a single base change (A>C) was introduced into the 
codon for amino acid 279 (Y279C) by site-directed mutagenesis. The point 
mutation and surrounding region were sequenced to verify the mutation 
and the fidelity of the amplification and then were subcloned into a modi-
fied neo cassette, consisting of a loxP511 site, the inverted mutant exon 
fragment, an inverted loxP site, an inverted loxP511 site, and a neo selection 
cassette flanked by FRT sites. This cassette was inserted by recombineering 
294 bp downstream of exon 7 to generate final targeting construct.
This construct was linearized with NotI, electroporated into TC1 
(129S6/SvEv) ES cells, and selected with G418 and FIAU. Resistant 
colonies were expanded and screened by long-range PCR, using primers 
outside and inside the targeting vector to identify homologous recom-
binants (see Supplemental Table 1). Recombinant clone 1F10 was used 
Figure 13
Rapamycin reverses HCM in LS/+ mice. (A) Representative echocardiographs from 16-week-old vehicle-treated WT, rapamycin-treated WT, 
vehicle-treated LS/+, or rapamycin-treated LS/+ mice. Two-headed arrows indicate left ventricle chamber size. (B) Anatomic and functional 
parameters of 12-, 16-, and 20-week-old WT, rapamycin-treated WT, LS/+, and rapamycin-treated LS/+ mice, as assessed by echocardiogra-
phy, either after 4 weeks (measured at 16 weeks of age) or after 4 weeks of daily i.p. injections, followed by 4 weeks of weekly (measured at 20 
weeks of age) i.p. injections. *P < 0.001, †P < 0.001, ‡P < 0.001. All P values were derived from ANOVA and Bonferroni post-test when ANOVA 
was significant.
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for blastocyst injection. Chimeras were generated (Brigham and Women’s 
Transgenic Core Facility), and germline transmission of iLS/+ mice was 
obtained. iLS/+ (129S6/SvEv × C57BL6/J) mice were crossed to Frt-Flp 
(C57BL6/J) mice (The Jackson Laboratory) to excise the neo cassette. iLS/+ 
mice with excised neo cassette were then crossed to EIIA-Cre (C57BL6/J) 
mice (The Jackson Laboratory), which express Cre ubiquitously, and then 
to WT (C57BL6/J) mice to generate mice with global LS Y279C expression 
(LS/+ mice). Subsequent generations of LS/+ mice were crossed to WT 
C57BL/J mice, thereby maintaining the line on a C57BL6/J background; 
these mice were used for all experiments. Genotyping was carried out by 
PCR using tail DNA (see Supplemental Table 1). Unless otherwise indi-
cated, WT C57BL6/J littermates were used as controls.
All animal studies were approved by the Beth Israel Deaconess Medi-
cal Center IACUC Committee and performed in accordance with IACUC 
standards. μCT scans (conducted at the Ontario Cancer Institute) were 
approved by the University Health Network Animal Care Commit-
tee and performed in accordance with the standards of the Canadian 
Council on Animal Care.
Body size analysis and morphometry
For growth curves, body length (anal-nasal length) and weight were measured 
biweekly. For skeletal morphometry using μCT, mice were anesthetized with 
2% isoflurane and scanned using a Locus Ultra MicroCT Scanner (GE Health-
care). Three-dimensional images of the skeleton were generated and analyzed 
with GEHC MicroView Software (GE Healthcare). Skull measurements were 
made according to the Standard Protocol and Procedures from The Jackson 
Laboratory (http://craniofacial.jax.org/standard_protocols.html).
Histology
Hearts for morphometry and histochemistry were flushed with PBS, 
perfusion fixed in formalin or Bouin’s reagent, and paraffin embedded. 
Sections (5 μm) were stained with H&E, Masson-Trichrome, or reticulin 
at the Rodent Histopathology Core at Harvard Medical School. Cross-
sectional length, width, and area of cardiomyocytes with centrally located 
nuclei (to ensure the same plane of sectioning) were measured using ImageJ 
1.41 software (developed by Wayne Rasband; http://rsbweb.nih.gov/ij/). 
Five individual samples were analyzed for each genotype, with 200–500 
cells measured in each.
Electron microscopy
Electron microscopy was performed at the Harvard Medical School Facil-
ity. Briefly, mouse hearts were perfused in PBS and fixed with a mixture of 
paraformaldehyde (2%) and glutaraldehyde (1.5%) in cacodylate buffer (0.1 M 
Na cacodylate, pH 7.4). Pieces (1 mm3) were dissected from the left ven-
tricle, postfixed in 1% OsO4, dehydrated in a series of alcohols, and embed-
ded in Epon Araldite (SPI Supplies). Ultrathin sections (silver to gold) were 
obtained with a Reichert Ultracut E microtome, stained with uranyl acetate 
and lead citrate, and observed in a Tecnai G2 Spirit BioTWIN (Tecnai), with 
an AMT 2k charge-coupled device camera.
Quantitative real-time PCR
RNA was isolated from whole hearts with TRIzol (Invitrogen) or using the 
RNeasy Mini Kit (QIAGEN). Quantitative real-time PCR was performed 
with SYBR Green (Applied Biosystems), using an Applied Biosystems 7900. 
Gene expression analyses for α-MHC, β-MHC, Anf, Bnp, SERCA2A, and Pln 
were carried out according to the manufacturer’s instructions. Primer 
sequences and conditions are listed (Supplemental Table 2). Each measure-
ment was obtained using at least 3 mice per group, and each sample was 
measured in triplicate. Data were quantified by using the comparative CT 
method, with Gapdh expression as a control.
Echocardiography
Transthoracic echocardiography was conducted on nonanesthetized 
animals as described previously (115), with a 13-MHz probe (Vivid 7, GE 
Medical Systems) or VisualSonics Vevo 770 high-frequency ultrasound 
rodent imaging system. GE Medical Systems or VisualSonics Vevo 770 
software was used for data acquisition and subsequent analysis. Hearts 
were imaged in the 2-dimensional parasternal short-axis view, and an 
Figure 14
Rapamycin treatment normalizes cardiac 
fetal gene expression in LS/+ mice. Total 
RNA from vehicle- or rapamycin-treated WT 
and LS/+ mice (n = 4–6 of each genotype) 
of the indicated ages was used to perform 
quantitative RT-PCR (each sample in tripli-
cate). The ratio of ΔδCT was analyzed using 
Gapdh as a control. Note that rapamycin-
treated LS/+ heart lysates have normalized 
fetal gene expression profiles as compared 
with those of WT heart lysates. Data repre-
sent mean ± SEM. *P < 0.01, †P < 0.001, 
2-tailed Student’s t test.
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M-mode echocardiogram of the midventricular region was recorded at 
the level of the papillary muscles. Calculations of cardiac anatomic and 
functional parameters were carried out as described previously (115).
Hemodynamic studies
Cardiac function was evaluated by measuring the maximum rate of increase 
(dP/dtmax) and decline (dP/dtmin) in left ventricular pressure with a micro-
manometer catheter (Millar 1.4F, SPR 671, Millar Instruments) positioned 
in the left ventricle via a right common carotid artery cannulation.
Biochemical analyses
Whole hearts from WT or LS/+ mice were dissected, perfused in PBS, and 
immediately frozen in liquid N2. Whole-cell lysates were prepared by homog-
enizing the tissue in radioimmunoprecipitation (RIPA) buffer (25 mmol/l 
Tris-HCl [pH 7.4], 150 mmol/l NaCl, 0.1% SDS, 1% NP-40, 0.5% sodium 
deoxycholate, 5 mmol/l EDTA, 1 mmol/l NaF, 1 mmol/l sodium orthovana-
date, and a protease cocktail) at 4°C, followed by clarification at 14,000 g.
Primary cardiomyocytes were isolated and cultured as previously described 
(116). Briefly, hearts were placed in a Langendorff apparatus, and adult 
cardiomyocytes were obtained by perfusion with Ca2+-free Tyrode buffer 
(135 mmol/l NaCl, 4 mmol/l KCl, 1 mmol/l MgCl2, 0.33 mmol/l NaH2PO4, 
10 mmol/l HEPES) (pH 7.4) and 10 mmol/l glucose, 10 mmol/l 2,3-butane-
dione monoxime (Sigma-Aldrich), and 5 mmol/l Taurine (Sigma-Aldrich) 
for 3 to 5 minutes. Perfusion was continued for an additional 7 to 10 min-
utes with recirculating Tyrode buffer, containing a mixture of collagenase D 
(0.3 mg/g body weight; Roche), collagenase B (0.4 mg/g body weight; Roche), 
and proteinase XIV (0.05 mg/g body weight; Sigma-Aldrich). Ventricular 
tissue was then minced in Tyrode solution containing 2% bovine serum 
albumin (Sigma-Aldrich), incubated for 15 minutes at 37°C, and filtered 
through a 250-μm nylon mesh. The cell suspension was centrifuged at 420 g 
for 2 minutes and then gradually subjected to Tyrode buffer containing 
increasing concentrations of calcium and decreasing concentrations of 
2,3-butanedione monoxime (i.e., the final concentration was 1.2 mmol/l CaCl2 
with no 2,3-butanedione monoxime). Typical yields were 1.5 × 106 to 2.5 × 106 
cells per heart, with 70% to 80% of the cells retaining their rod-shaped morphol-
ogy. After 12 hours, cardiomyocytes were stimulated for the indicated times 
with the appropriate agonist (10 nmol/l IGF-1, 25 ng/ml EGF, 100 nmol/l 
angiotensin II, 10 ng/ml IL-6), washed, and lysed either directly in sample buf-
fer containing SDS or in RIPA at 4°C, followed by clarification at 14,000 g.
After 12 hours, cardiomyocytes were stimulated for the indicated times with 
the appropriate agonist (10 nmol/l IGF-1, 25 ng/ml EGF, 100 nmol/l angio-
tensin II, or 10 ng/ml IL6), washed, and either lysed in RIPA buffer at 4°C, 
followed by clarification at 14,000 g, or directly in SDS-PAGE sample buffer. 
Proteins were resolved by SDS-PAGE and transferred to PVDF membranes. 
Immunoprecipitations were performed with either anti-Gab1 or anti–IRS-1 
antibodies (Cell Signaling Technology). Immunoblots were performed, fol-
lowing the manufacturer’s directions, with anti-Akt, anti-JNK, anti-GSK-3α, 
anti-phospho-FAK-297, or anti-Shp2 antibodies (all from Santa Cruz Biotech-
nology Inc.); anti-Stat3, anti-Erk1/2, anti-Gab1, anti–IRS-1, anti-TSC21462, or 
anti-p70S6 kinase antibodies (all from Cell Signaling Technology); or anti-
phospho-Akt473, anti-phospho-Erk1/2, anti-phospho-Stat 3, anti-phospho-
JNK, anti-phospho-TSC21462, anti-phospho-p70S6 kinase, or anti-phospho-
GSK-3α antibodies (all from Cell Signaling Technology). Bands were visualized 
with enhanced chemiluminescence and quantified by densitometry (developed 
by Wayne Rasband; ImageJ 1.41 software, http://rsbweb.nih.gov/ij/).
Immune complex PTP assays
PTP assays were conducted as previously described (39) using para-
nitrophenyl phosphate (pNPP, obtained from Sigma-Aldrich) as sub-
strate. WT or LS/+ whole heart lysates were homogenized and lysed 
in RIPA buffer (but without sodium orthovanadate), and Shp2 was 
immunoprecipitated by using anti-Shp2 polyclonal antibodies (Santa 
Cruz Biotechnology Inc.) coupled to protein A-Sepharose. Immune 
complexes were washed 3 times in RIPA buffer without sodium 
orthovanadate and once in wash buffer (30 mm HEPES [pH 7.4], 120 
mm NaCl without pNPP). For each sample, PTP assays were performed 
in triplicate at 37°C in 50 μl assay buffer (30 mm HEPES [pH 7.4], 
120 mm NaCl, 5 mm dithiothreitol, 10 mm pNPP) containing 50 μl 
of the Shp2 beads. Reactions were terminated with 0.2 N NaOH, and 
phosphate release was determined by measuring A410. After the assays, 
immune complexes were recovered by centrifugation, boiled in 2× SDS-
PAGE sample buffer, resolved by SDS-PAGE, and immunoblotted with 
polyclonal Shp2 antibodies (Santa Cruz Biotechnology Inc.) to ensure 
that equal amounts of Shp2 had been tested for phosphatase activity.
Rapamycin studies
In vitro. When indicated, primary cardiomyocytes were treated in vitro with 
rapamycin (Sigma-Aldrich) dissolved in DMSO at 0.02 μM or DMSO alone 
for 12 hours.
In vivo. Rapamycin (LC Laboratories) was dissolved in ethanol at a con-
centration of 20 mg/ml, filter sterilized, resuspended in vehicle (0.25% PEG, 
0.25% Tween-80) at a concentration of 1 mg/ml, and injected i.p. (2 mg/kg 
body weight), either daily for 4 weeks or daily for 4 weeks followed by week-
ly injections for an additional 4 weeks. Injections began at either 8 weeks 
(prior to onset of hypertrophy) or 12 weeks (after established hypertrophy 
was indicated) of age, and mice were assessed after 4 weeks of treatment or 
after 8 weeks of treatment, as detailed in the Results and figure legends. As 
controls, WT and LS/+ mice were treated with vehicle alone.
In vitro Jnk and Stat3 inhibition experiments. When indicated, similarly to 
rapamycin treatment, primary cardiomyocytes were treated in vitro with 
either Jnk Inhibitor II (Calbiochem) or Stat Inhibitor V (Santa Cruz) dis-
solved in DMSO at 10 μM and 1 μM, respectively.
Statistics
All data are expressed as mean ± SEM. Statistical significance was deter-
mined using 2-tailed Student’s t test and 1-way ANOVA or 2-way repeated 
measure ANOVA, as appropriate. If ANOVA was significant, individual 
differences were evaluated using the Bonferroni post-test. Kaplan-Meier 
survival curves were analyzed using the log-rank test. For all studies, values 
of P < 0.05 were considered statistically significant.
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